Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2022-03-08 00:00:00 ET · period of report 2022-03-04 · accession 0001209191-22-017318 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $3.67 | +7,406 | 38.9K | +23% | +$27.2K |
| D | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $31.42 | -696 | 32.8K | -2% | -$21.9K |
| DM | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $30.50 | -21.7K | 32.2K | -40% | -$662.2K |
| DM | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $0.00 | -7,406 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-03-04 | M | A | 1,234 | $3.67 | 33,466 | D | — | — | (F1) The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. |
| 2 | Common | Common Shares | 2022-03-04 | F | D | 696 | $31.42 | 32,770 | D | — | — | (F2) Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 3 | Common | Common Shares | 2022-03-04 | M | A | 6,172 | $3.67 | 38,942 | D | — | — | (F1) The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. |
| 4 | Common | Common Shares | 2022-03-04 | S | D | 5,000 | $30.23 | 17,232 | D | — | — | (F5) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 5 | Common | Common Shares | 2022-03-04 | S | D | 5,000 | $30.15 | 27,232 | D | — | — | (F3) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 6 | Common | Common Shares | 2022-03-04 | S | D | 5,000 | $31.05 | 22,232 | D | — | — | (F4) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 7 | Common | Common Shares | 2022-03-04 | S | D | 6,710 | $30.56 | 32,232 | D | — | — | (F2) Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. |
| 8 | Derivative | Stock Option (Right to Buy) | 2022-03-04 | M | D | 1,234 | $0.00 | 0 | D | $3.67 · — to 2022-03-10 | 1,234 Common Shares | (F1) The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. (F6) 1/3 of the shares subject to the Option vested on January 1, 2012 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years. (F7) Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. |
| 9 | Derivative | Stock Option (Right to Buy) | 2022-03-04 | M | D | 6,172 | $0.00 | 0 | D | $3.67 · — to 2022-03-10 | 6,172 Common Shares | (F1) The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. (F8) 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date (F7) Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. |